Recent

% | $
Quotes you view appear here for quick access.

SciClone Pharmaceuticals, Inc. Message Board

  • usualsuspect9753 usualsuspect9753 Jan 28, 2013 10:20 AM Flag

    Can Sinopharm take zadaxin into new markets?

    Not only does Sinopharm control 72.38% of the Chinese market, they are in South America, Asia, Europe, and more.
    Sinopharm has launched various international projects of technological cooperation in many countries and
    established a trading partnership with more than 100 countries and regions in the world, which facilitates the upgrading and improvement of manufacturing capability and management of pharmaceutical industry. In 2010, the revenue of Sinopharm reached approximately RMB 100 billion yuan. The goal of Sinopharm is to become one of the TOP 500 enterprises in the world and an internationally competitive leader in the pharmaceutical industry within the period of “Twelfth Five-Year Plan” (2011-2015).

    According to the overall strategic plan of Sinopharm, Sinopharm International undertakes the responsibility to accelerate the development of both international business and domestic pharmaceutical and healthcare industry as well. In an effort to become the largest international pharmaceutical group in China, Sinopharm International is active to develop its main business in four catagories including international medicine trading business, pharmaceutical enterprises in overseas, industrialization of healthcare and medical services, healthcare product industry to make a positive contribution to public health and fullfill it’s obligation for the social community.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Been awhile since these have been posted...Zadaxin approved in these countries, but from what I see has a very small presence. I have heard of people going to Mexico for "Z"

      Argentina, Azerbaijan, Bahrain, Brunei, Cambodia, China, Dominican Republic, Hong Kong, India, Indonesia, Kuwait, Kazakhstan, Kyrgyzstan, Laos, Malaysia, Maldives, Malta, Mexico, Moldova, Pakistan, Peru, Philippines, Russia, Singapore, Sri Lanka, Thailand, Ukraine, United Arab Emirates, Uzbekistan, Venezuela, Vietnam

      Chronic Hepatitis B

      Marketing Approval
      Argentina, Dominican Republic, Mexico, Peru, Philippines, Russia, Singapore, Sri Lanka, Thailand, Ukraine

      Chronic Hepatitis C

      Marketing Approval
      Philippines, Sri Lanka, Thailand

      Cancer Adjuvant

      Marketing Approval
      Argentina, China, Dominican Republic, Hong Kong, Italy, Mexico, Philippines, South Korea, Thailand

      Vaccine Enhancer

      Marketing Approval
      Brazil, Georgia, Myanmar, Peru

      Immunostimulant

      Marketing Approval
      Europe

      Malignant Melanoma

      Completed Phase 2
      Europe

      Chronic Hepatitis C

      Completed Phase 3
      United States

      Liver Cancer

      Completed Phase 2

 
SCLN
8.96-0.13(-1.43%)Apr 24 4:00 PMEDT